IFP Advisors’s Akebia Therapeutics AKBA Stock Holding History

IFP Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-52	Closed	-$84	–	5020
2025 Q4	$84	Buy	52 +9	+21%	+$19	﹤0.01%	4626
2025 Q3	$117	Buy	+43	New	+$143	﹤0.01%	4517
2025 Q2	–	Hold	0	–	–	–	3345
2021 Q4	–	Sell	-152	Closed	-$1K	–	3376
2021 Q3	$1K	Buy	152 +50	+49%	+$143	﹤0.01%	2966
2021 Q2	$0	Buy	+102	New	+$343	﹤0.01%	3049
2020 Q4	–	Sell	-47	Closed	-$137	–	2927
2020 Q3	$0	Buy	+47	New	+$412	﹤0.01%	2833
2018 Q3	–	Sell	-28	Closed	–	–	3804
2018 Q2	$0	Sell	28 -400	-93%	-$4K	﹤0.01%	3856
2018 Q1	$6K	Hold	428	–	–	﹤0.01%	3044
2017 Q4	$6K	Buy	428 +400	+1,429%	+$6.63K	﹤0.01%	3090
2017 Q3	$1K	Hold	28	–	–	﹤0.01%	3865
2017 Q2	$0	Hold	28	–	–	﹤0.01%	4061
2017 Q1	$0	Hold	28	–	–	﹤0.01%	3966
2016 Q4	$0	Hold	28	–	–	﹤0.01%	3958
2016 Q3	$0	Buy	+28	New	+$238	﹤0.01%	3884
2016 Q1	–	Sell	-77	Closed	-$1K	–	2371
2015 Q4	$1K	Buy	+77	New	+$786	﹤0.01%	3470

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

IFP Advisors's AKBA Position: Q1 2026 in Review

IFP Advisors sold out of Akebia Therapeutics (AKBA) in Q1 2026, closing a stake of 52 shares — an estimated $84 sold.

IFP Advisors first reported a position in AKBA in Q4 2015 and held it in 14 quarters. The position peaked at $6K in Q1 2018. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

IFP Advisors reported no remaining Akebia Therapeutics position as of Q1 2026 after selling out during the quarter.
IFP Advisors sold 52 Akebia Therapeutics shares in Q1 2026, an estimated $84.
IFP Advisors first reported a position in Akebia Therapeutics in Q4 2015 and held it in 14 quarters.
IFP Advisors's Akebia Therapeutics position peaked at $6K in Q1 2018.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on IFP Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.